GLP-1 Science
GLP-1 and Smoking Cessation Research
Emerging research suggests semaglutide may reduce tobacco use, an unexpected finding still being actively studied. Here...
Migraine and headache more generally are covered from a side-effect angle in our headaches guide. This article covers a different, more surprising finding: emerging evidence that a GLP-1 medication may actually reduce migraine frequency for some people.
What the study found
A prospective pilot study published in the journal Headache in 2025 enrolled 31 patients with obesity and high-frequency or chronic migraine who had not responded adequately to at least two prior preventive treatments. Participants received liraglutide 1.2 mg daily as an add-on to their existing migraine management, over a 12-week follow-up period.
The study found a mean reduction of approximately 9.1 monthly migraine days, with patients reporting roughly 11 fewer headache days per month overall, alongside a substantial improvement in migraine-related disability scores.
The genuinely notable finding: independent of weight loss
The reduction in migraine days appeared independent of the amount of weight lost, suggesting the effect is not simply explained by weight loss itself, unlike some of the other benefits covered throughout this series. This points toward a more direct mechanism.
The proposed mechanism
GLP-1 receptor agonists have been shown in prior research to reduce intracranial pressure, and separately to decrease expression of calcitonin gene-related peptide, a molecule specifically implicated in migraine pathophysiology and already the target of a dedicated class of migraine medications. Both mechanisms offer a plausible biological explanation independent of appetite or weight effects.
Why this evidence needs careful interpretation
This was a small, open-label pilot study, 31 participants, without a placebo control group. Open-label studies, where both patients and researchers know what treatment is being given, are more susceptible to bias than blinded, placebo-controlled trials, and results in a larger controlled trial could look different.
It studied liraglutide specifically, at a specific dose, in patients selected for both obesity and treatment-resistant chronic migraine. It does not establish an effect in migraine patients without obesity, or necessarily with other GLP-1 medications at different doses.
It is not an approved treatment for migraine. GLP-1 medications remain approved for diabetes and weight management; migraine is not a labelled indication, and this remains investigational.
What this means practically today
If you have both obesity and migraine, particularly migraine that has not responded well to standard preventive treatments, this is a genuinely interesting area to discuss with your neurologist and weight management doctor together, alongside, not instead of, established migraine treatments with a larger evidence base.
Where this applies to sublingual products
This specific finding relates to pharmaceutical liraglutide at a defined injectable dose, and GLP-1 appetite support you hold under the tongue has not been studied for any effect on migraine frequency. METASLIM™ is a physician-reviewed sublingual supplement for weight management through the GLP-1 appetite pathway, and it should not be used or considered as a migraine treatment based on this early research.
Get started with a physician review to discuss your overall health picture, including migraine history, as part of a properly individualised assessment.
The summary
A 2025 pilot study found liraglutide reduced monthly migraine days by roughly half in patients with obesity and chronic migraine unresponsive to standard treatments.
The reduction appeared independent of weight loss, pointing toward a separate mechanism involving intracranial pressure and calcitonin gene-related peptide.
This was a small, open-label study without a placebo control, so results should be interpreted cautiously pending larger controlled trials.
GLP-1 medications are not approved for migraine treatment, and this evidence should be discussed with, not substituted for, established migraine care.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.